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T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer that is
mainly diagnosed in children and arises from the malignant transformation of T cell progeni-
tors [1]. Current treatment protocols consist of high-dose, multi-agent combination chemo-
therapy and result in cure rates of greater than 85% in children. However, despite their clinical
success, the toxic nature of these aggressive treatment regimens causes severe side effects such
as reduced intellectual capacity, osteonecrosis and growth deficiencies, infertility, and an
increased risk of secondary tumor development later in life. Therefore, integration of novel
targeted therapies into contemporary T-ALL treatment protocols will be required to increase
the quality of life for pediatric T-ALL survivors [2].
Glucocorticoids, such as prednisone or dexamethasone, are core components of the high-
dose chemotherapy schedules used for the treatment of T-ALL [3]. The apoptotic response
induced by these glucocorticoids is mediated by their interaction with the glucocorticoid
receptor NR3C1 (Fig 1). Upon ligand binding, NR3C1 undergoes dimerization and translo-
cates to the nucleus in order to regulate target gene expression through direct interaction with
a specific DNA binding motif (glucocorticoid response element) [3]. One important glucocor-
ticoid target gene is the pro-apoptotic BCL2 family member BCL2L11 (encoding the BIM pro-
tein), which counteracts the anti-apoptotic activity of BCL2, BCL-XL, and MCL1 and will
trigger a steroid-induced apoptotic response in steroid-sensitive leukemic blasts (Fig 1). Nev-
ertheless, glucocorticoid response is variable amongst T cell leukemia patients, and steroid
resistance has been associated with an increased risk of relapse and poor clinical outcome [3].
Therefore, increased understanding of the molecular mechanisms that drive glucocorticoid
resistance in human T-ALL could trigger the development of novel strategies that restore ste-
roid sensitivity in this disease. Ultimately, these efforts should improve clinical outcome in
human T-ALL and reduce the detrimental toxic side effects associated with high-dose
chemotherapy.
Genetics Meet Drug Sensitivity in Human T-ALL
In this issue of PLOS Medicine, Jules Meijerink and colleagues [4] integrated next-generation
sequencing data and genome-wide copy number profiles with ex vivo drug sensitivity and clin-
ical outcome in a large panel of primary T-ALL specimens obtained at diagnosis. Interestingly,
the authors found that mutations in the interleukin 7 receptor (IL7R) signaling pathway,
including JAK1 and KRAS mutations, were significantly associated with prednisolone resis-
tance and reduced survival in an initial discovery cohort of 69 primary T-ALL samples. Of
note, these results are in line with the poor prognostic implications of JAK1 [5] and N/K-RAS
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[6] mutations that have previously been reported in adult T-ALL. In addition, previous studies
have also shown an association between RAS mutations and steroid resistance in the context
of precursor B-lineage ALL (B cell acute lymphoblastic leukemia [B-ALL]) [7,8]. Given that
various mutations affecting the IL7R signaling cascade have also been reported in precursor
B-ALL, it is tempting to speculate that the relation between IL7R signaling and steroid resis-
tance could be a general feature of both T- and B-lineage ALL.
Next, Meijerink and colleagues extended their analyses to 146 leukemia samples, for which
they determined the mutational status of a selected panel of genes required for IL7R–RAS–
MAPK–AKT signaling (IL7Ra, JAK1, JAK3, NF1, NRAS, KRAS, and AKT) by PCR-based
Sanger sequencing. This analysis revealed that T-ALL specimens mutated for any of these
genes were significantly associated with steroid resistance and poor clinical outcome. Interest-
ingly, T-ALLs that harbor mutations in IL7R–RAS–MAPK–AKT signaling were associated
with specific molecular genetic subtypes, including immature, TLX1, TLX3-rearranged, or
HOXA-activated leukemias. However, it should be noted that Meijerink and colleagues are the
first to establish that these specific genetic alterations are truly associated with steroid resis-
tance in primary T-ALL specimens.
Fig 1. The glucocorticoid response in T-ALL. In steroid-sensitive T-ALL cells, steroid-mediated activation, dimerization, and subsequent
nuclear translocation of the steroid receptor NR3C1 results in transactivation of the pro-apoptotic BIM and PUMA, which will activate the
apoptosome complex after cytochrome C release from the mitochondria. The anti-apoptotic protein MCL1 in steroid-sensitive T-ALL cells is
actively targeted for proteasomal degradation via GSK3β. βP, phosphorylation; Ub, ubiquination; GRE, glucocorticoid response element.
doi:10.1371/journal.pmed.1002208.g001
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From Association to Functional Implications: Genetic Drivers of
Steroid Resistance
To functionally validate the putative contribution of each of these mutations to steroid resis-
tance in T-ALL, Meijerink and colleagues generated a panel of isogenic tumor lines with
inducible expression of IL7R–RAS–MAPK–AKT pathway mutations. Using these elegant in
vitro model systems, the authors confirmed that IL7R, JAK1, and NRAS mutations, as well as
overexpression of wild-type NRAS or AKT, could drive steroid resistance in human T-ALL
cell lines (Fig 2). In contrast, no effect was observed for mutant JAK3 or expression of wild-
type JAK1, JAK3, or IL7R.
Notably, no differences in NR3C1 nuclear translocation or target gene transactivation upon
glucocorticoid exposure were observed between steroid-resistant and steroid-sensitive isogenic
tumor cell lines. These data suggest that, at least in these in vitro model systems, the molecular
mechanisms controlling steroid resistance are downstream or independent of the NR3C1
transactivation response. Strikingly, these results are in sharp contrast with other work in
which glucocorticoid resistance in ALL was associated with the inability to induce the pro-
apoptotic NR3C1 target gene BCL2L11 upon dexamethasone treatment of patient-derived
Fig 2. Molecular mechanisms that drive glucocorticoid resistance in T-ALL. In steroid-resistant T-ALL cells, the JAK/STAT, RAS/pERK,
and PI3K/AKT1/mTOR signaling pathways result in: (1) up-regulation of the anti-apoptotic proteins BCL2 and BCL-XL; (2) inactivation of
GSK3β, leading to increased concentrations of the anti-apoptotic protein MCL1; and (3) direct inhibition of BIM, which collectively counteract
the NR3C1-mediated activation of the apoptosome complex. P, phosphorylation; GRE, glucocorticoid response element.
doi:10.1371/journal.pmed.1002208.g002
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xenografts [9,10]. These contradictory results may be related to a differential epigenetic state
of the BCL2L11 (BIM) locus in the T-ALL cell lines versus patient-derived xenografts. In addi-
tion, these results suggest that steroid resistance can be gained via various means at different
essential nodes in these converging signaling pathways.
Instead of a dysfunctional glucocorticoid-induced transcriptional response, Meijerink and
colleagues identified aberrant activation of specific signaling pathways downstream of mutant
IL7R, JAK1 or NRAS, or wild-type AKT as major determinants of steroid resistance in the iso-
genic tumor lines (Fig 2). Indeed, expression of IL7R, JAK1, or NRAS mutations provoked a
strong activation of MEK–ERK and AKT signaling with concomitant phosphorylation of
p70-S6K and an increased expression of anti-apoptotic BCL-XL. In addition, activated MEK–
ERK and AKT signaling also triggered a robust inactivation of GSK3β, which would lead to
stabilization of anti-apoptotic MCL1 (Fig 2). Interestingly, the association between IL7R–JAK
signaling and steroid resistance described in this study is in line with the interleukin 7-induced
anti-apoptotic rescue of primary T-ALLs against dexamethasone, as reported more than a
decade ago [11]. However, in these studies, the inhibition of apoptosis by interleukin 7 was
shown to correlate with up-regulation of BCL2 [12]. In addition, recurrent mutations in the
IL7R and RAS signaling pathways mainly occur in early immature T-ALLs, which are also
more often characterized by increased concentrations of BCL2 [13,14].
Small Molecules with a Future in Steroid-Resistant T-ALL
Meijerink and colleagues’ study has unraveled specific pathways that influence glucocorticoid
sensitivity in T-ALL by affecting the balance between pro- and anti-apoptotic factors. There-
fore, specific targeting of these signaling cascades could provide a unique opportunity to over-
come glucocorticoid resistance in human T-ALL. Indeed, the JAK1 inhibitor ruxolitinib, the
MEK inhibitor CI1040, and the AKT inhibitor MK2206 were able to reverse steroid resistance
in specific isogenic tumor lines (Fig 3). Interestingly, the authors also showed that the GSK3β
inhibitor IX provoked strong steroid resistance in sensitive T-ALL tumor lines, further con-
firming the pivotal role of this molecule in the regulation of glucocorticoid resistance. More-
over, given the central role for the balance between pro- and anti-apoptotic factors in this
process, one could hypothesize that specific targeting of the apoptotic machinery using BCL2
[13] or MCL1 [15] inhibitors could also serve as a useful strategy to alter steroid resistance in
the context of malignant T cell transformation.
In a more clinically relevant approach, the authors subsequently evaluated the putative drug
synergism between prednisolone and seven small molecule inhibitors targeting JAK1, MEK1/
2, or PI3K/AKT/mTOR in a panel of 11 genetically well-characterized primary T-ALL samples
at diagnosis. Notably, small molecule inhibitors targeting MEK–ERK or PI3K/AKT/mTOR
signaling enhanced the steroid response in most primary T-ALL samples (Fig 3). In line with
this notion, recent work showed that the dual PI3K/AKT/mTOR inhibitor BEZ235 enhanced
dexamethasone sensitivity in vivo using a patient-derived T-ALL xenograft [16]. Surprisingly,
and in contrast with the cell line data, ruxolitinib had a synergistic effect on prednisolone treat-
ment in only 1 out of 11 primary T-ALL samples. However, this might be related to the lack of
proliferative capacity of T-ALL cells in this system, given that previous work convincingly
showed preclinical in vivo efficacy of ruxolitinib in patient-derived T-ALL xenografts [14].
Nevertheless, these results could suggest that ruxolitinib might not be suitable for therapeutic
targeting of dormant leukemic stem cells.
In conclusion, Meijerink and colleagues’ study nicely illustrates how somatic alterations
implicated in T-ALL disease biology influence the differential steroid response observed in the
clinic. These novel insights strongly suggest that inhibition of MEK–ERK or PI3K/AKT/mTOR
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signaling could enhance steroid sensitivity in T-ALL and potentially improve patient treatment
outcome, a notion that warrants further investigation in future prospective clinical trials.
References
1. Durinck K, Goossens S, Peirs S, Wallaert A, Van Loocke W, Matthijssens F, et al. Novel biological
insights in T cell acute lymphoblastic leukemia. Exp Hematol. 2015; 43(8):625–39. doi: 10.1016/j.
exphem.2015.05.017 PMID: 26123366
2. Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015; 373
(16):1541–52. doi: 10.1056/NEJMra1400972 PMID: 26465987
3. Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010; 11
(11):1096–106. doi: 10.1016/S1470-2045(10)70114-5 PMID: 20947430
4. Li Y, Buijs-Gladdines JG, Cante´-Barrett K, Stubbs AP, Vroegindeweij EM, et al. IL-7 Receptor Mutations
and Steroid Resistance in Pediatric T Cell Acute Lymphoblastic Leukemia: A Genome Sequencing
Study. PLoS Med. 2016; 13(12):e1002200. doi: 10.1371/journal.pmed.1002200
5. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, et al. Somatically acquired JAK1
mutations in adult acute lymphoblastic leukemia. J Exp Med. 2008; 205(4):751–8. doi: 10.1084/jem.
20072182 PMID: 18362173
6. Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, Lambert J, Beldjord K, Lengline E, et al. Toward a
NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T cell acute lymphoblastic
Fig 3. Small molecule inhibitors that reverse glucocorticoid resistance in T-ALL. Small molecules targeting JAK1, MEK1/2, or PI3K/
AKT/mTOR (marked in red) in synergy with glucocorticoids can serve as a useful strategy to overcome steroid resistance in the context of
malignant T cell transformation. P, phosphorylation; Ub, ubiquination; GRE, glucocorticoid response element.
doi:10.1371/journal.pmed.1002208.g003
PLOS Medicine | DOI:10.1371/journal.pmed.1002208 December 20, 2016 5 / 6
leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol. 2013; 31
(34):4333–42. doi: 10.1200/JCO.2012.48.5292 PMID: 24166518
7. Aries IM, van den Dungen RE, Koudijs MJ, Cuppen E, Voest E, Molenaar JJ, et al. Towards personal-
ized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance.
Haematologica. 2015; 100(4):e132–6. doi: 10.3324/haematol.2014.112995 PMID: 25480501
8. Irving J, Matheson E, Minto L, Blair H, Case M, Halsey C, et al. Ras pathway mutations are prevalent in
relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;
124(23):3420–30. doi: 10.1182/blood-2014-04-531871 PMID: 25253770
9. Jing D, Bhadri VA, Beck D, Thoms JA, Yakob NA, Wong JW, et al. Opposing regulation of BIM and
BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells. Blood.
2015; 125(2):273–83. doi: 10.1182/blood-2014-05-576470 PMID: 25336632
10. Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, Mogavero A, et al. Epigenetic silencing of
BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by his-
tone deacetylase inhibition. Blood. 2010; 116(16):3013–22. doi: 10.1182/blood-2010-05-284968 PMID:
20647567
11. Wuchter C, Ruppert V, Schrappe M, Dorken B, Ludwig WD, Karawajew L. In vitro susceptibility to dexa-
methasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsive-
ness to interleukin 7, and early cytoreduction in vivo in childhood T cell acute lymphoblastic leukemia.
Blood. 2002; 99(11):4109–15. PMID: 12010814
12. Karawajew L, Ruppert V, Wuchter C, Kosser A, Schrappe M, Dorken B, et al. Inhibition of in vitro spon-
taneous apoptosis by IL-7 correlates with bcl-2 up-regulation, cortical/mature immunophenotype, and
better early cytoreduction of childhood T cell acute lymphoblastic leukemia. Blood. 2000; 96(1):297–
306. PMID: 10891465
13. Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, et al. ABT-199 mediated
inhibition of BCL-2 as a novel therapeutic strategy in T cell acute lymphoblastic leukemia. Blood. 2014;
124(25):3738–47. doi: 10.1182/blood-2014-05-574566 PMID: 25301704
14. Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, et al. Efficacy of JAK/
STAT pathway inhibition in murine xenograft models of early T cell precursor (ETP) acute lymphoblastic
leukemia. Blood. 2015; 125(11):1759–67. doi: 10.1182/blood-2014-06-580480 PMID: 25645356
15. Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhib-
itor S63845 is tolerable and effective in diverse cancer models. Nature. 2016; 538(7626):477–82. doi:
10.1038/nature19830 PMID: 27760111
16. Hall CP, Reynolds CP, Kang MH. Modulation of Glucocorticoid Resistance in Pediatric T cell Acute
Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235. Clin
Cancer Res. 2016; 22(3):621–32. doi: 10.1158/1078-0432.CCR-15-0114 PMID: 26080839
PLOS Medicine | DOI:10.1371/journal.pmed.1002208 December 20, 2016 6 / 6
